EMG
RPTP

Ellington Management Group’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

Ellington Management Group’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-16,600
Closed -$216K – 929
2013
Q4 		$216K Buy
+16,600
New +$229K 0.08% 428

Other funds holding RPTP

CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Ellington Management Group's RPTP Position: Q1 2014 in Review

Ellington Management Group sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q1 2014, closing a stake of 16,600 shares — an estimated $216K sold.

Ellington Management Group first reported a position in RPTP in Q4 2013 and held it in 1 quarter. The position peaked at $216K in Q4 2013. 71 funds tracked by Wall St. Rank hold RPTP as of Q1 2014.

  • Ellington Management Group reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q1 2014 after selling out during the quarter.
  • Ellington Management Group sold 16,600 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q1 2014, an estimated $216K.
  • Ellington Management Group first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2013 and held it in 1 quarter.
  • Ellington Management Group's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $216K in Q4 2013.
  • 71 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q1 2014.

Based on Ellington Management Group's 13F filing for Q1 2014, filed 15 May 2014.